GUIDELINES FOR THE SAFE PRESCRIBING OF MELATONIN IN CHILDREN WITH NEURODEVELOPMENTAL DISORDERS//NEURODISABILITIES

Community Child Health
East and North Hertfordshire NHS Trust

Date: March 2014
Review Date: March 2016

Authors:
Dr Susan Ozer (Consultant Community Paediatrician)
Dr Nivedita Bajaj (Consultant Community Paediatrician)

Acknowledgements:
Dr Jon Keene, Specialist Registrar, Community Child Health
Sue Briars, Paediatric Pharmacist
All Community Paediatricians
East and North Hertfordshire NHS Trust
## Contents

- Key points for implementation (practical guidance)  
  - P. 3
- Rationale for a Melatonin Guideline  
  - P. 4
- Background: Sleep and Melatonin  
  - P. 4
- What is Melatonin?  
  - P. 5
- Efficacy  
  - P. 5
- Indications  
  - P. 5
- Cautions  
  - P. 5
- Side-effects  
  - P. 5
- Contraindication  
  - P. 6
- Doses and Administration  
  - P. 6
- Duration of Treatment  
  - P. 6
- Reviewing Treatment  
  - P. 6
- Monitoring  
  - P. 7
- Licensing  
  - P. 7
- Melatonin formulation/Cost  
  - P. 7
- Specialist Paediatrician responsibilities  
  - P. 9
- GP/ Primary Health Care Professional responsibilities  
  - P. 9
- Hospital Pharmacist responsibilities  
  - P. 9
- Parent/Carer and patient responsibilities  
  - P. 9
- References  
  - P. 10
Key points for implementation (practical guidance)

- Before initiating melatonin good sleep hygiene methods should have been tried for more than 6 months and failed in achieving a normal sleep pattern. There is evidence that sleep difficulties is impairing daytime functioning. **Refer to attached sleep flow chart, check list and sleep pack for parents/carers.**

- Melatonin should only be initiated in children/young people with Neurodevelopmental disorders/neurodisabilities with sleep rhythm disturbances.

- Sleep hygiene should be checked regularly (3-6 monthly) in all children commenced on melatonin.

- Children on melatonin should be monitored regularly (3-6 months) for side effects and efficacy.

- Regular trials off melatonin (6 monthly ‘washouts’) are required to review the need for long term use of melatonin use in certain groups of children. ‘Washouts’ should ideally occur during school holidays to minimize disruption to the child and family. Withdrawal of melatonin particularly if the child is on high doses may be considered for a gradual withdrawal, over 2-3 weeks.

- Following withdrawal, sleep pattern should be monitored for improvement. For very small groups of children, withdrawal may be unsuccessful thus necessitating long term use of melatonin.

- Melatonin may be used for short periods (3-6 months) to help establish a normal sleep pattern in certain groups of children e.g. exams/stressful events.

- Parent/Carer information on melatonin should include sleep hygiene, duration of treatment, approximate time and duration of melatonin washouts if applicable and clear instructions on how to return sleep feedback to the CDC and the method of sleep review.

- The licensed product Circadin® 2mg tablets (modified release) should be offered as first line in an off label way whenever possible. Circadin can be crushed to provide an immediate release profile.

- Biomalatin (Pharmanord) 3 mg tablets (immediate release) licensed in Europe can be used as second line particularly for children who have difficulties with swallowing tablets. Biomalatin should be prescribed in-house by the hospital pharmacy and not on FP10s.

- Liquid melatonin prescriptions should not be prescribed without discussion with the Paediatric Pharmacist.

- Most melatonin formulations are significantly more expensive than Circadin or Biomalatin preparations.

- **With effect from 1st May 2014, all melatonin prescriptions including circadin should be prescribed on hospital scripts, not FP10. Exceptions to this include patients travelling a long distance to the hospital e.g. Hertford County clinics or...**
carers with profound disabilities making it difficult to travel to the Hospital pharmacy. Copies of melatonin FP10s should be sent to Sue Briars (Paediatric Pharmacist for monitoring and audit purposes).

Rationale for a Melatonin Guideline:

1. Increase in Melatonin East/North Hertfordshire NHS Trust spend in the last 10 years.
   Melatonin annual spend East/North Hertfordshire NHS Trust- £45,000/year. For Hertfordshire and Hertfordshire Valley, the total annual spend on melatonin products was £344,180 over the same timeframe. Of this £254,257 was accounted for by specials melatonin.

2. Scientific evidence to support long term use of Melatonin (efficacy/safety) is limited.

Background: Sleep and Melatonin

Sleep disturbances are common in children with ASD and other neurodevelopmental disorders. They occur in approximately 80% of children with moderate to severe neurodevelopmental disorders. Sleep difficulties have also been reported in children with ADHD, visual impairments, Retts syndrome, epilepsy and brain damaged children. The prevalence of circadian rhythm sleep disorders in children with neurodevelopmental disorders is higher than typically developing children due to an association with abnormal melatonin secretion.
What is Melatonin?

Melatonin is an endogenous substance produced in the pineal gland located in the brain. It has the important role of regulating circadian rhythms. Melatonin responds to decreasing light levels at night and increase in light levels during the day.

In humans endogenous melatonin production starts soon after dark, peaks in the middle of the night (2-4am) and gradually declines during the second half of the night. Half life of natural melatonin is approximately 40 minutes.

Efficacy

There is limited evidence that melatonin can reduce sleep latency, maintain sleep and increase overall sleep efficiency in children with neurodevelopmental disorders. Only few of the studies however have been well designed, controlled and long term \(^1,2,3,6\)

Indications

For treating sleep onset insomnia and delayed sleep phase syndrome in children with conditions such as

- Visual impairment,
- Cerebral palsy,
- Attention deficit hyperactivity disorder,
- Autism,
- Learning difficulties,
- Epilepsy and Neurodegenerative disorder

* The use of melatonin is supported by NICE in the clinical guideline on the diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in children.\(^{20}\)

Cautions

Autoimmune diseases, hepatic diseases, renal diseases.

Side-effects

The most commonly reported side effects are headaches, nausea, dizziness and drowsiness.

Very occasionally children can show a paradoxical reaction of overactivity and irritability.

There are also concerns that melatonin may adversely affect seizure control, gonadal
development and asthma control and at present there are no data available to support or refute any of these concerns.

**Contraindication**

Hypersensitivity to the active substance or to any of the excipients.

**Doses and Administration**

Child 1 month–18 years initially 2–3 mg daily before bedtime increased if necessary after 1–2 weeks to 4–6 mg daily before bedtime; max. 10 mg daily.

Doses higher than 10mg are not considered to be of greater efficacy and may cause increased side-effects.

**Circadin** should be taken 1-2 hours before bedtime and after food. This dosage may be continued for up to thirteen weeks.

**Bio-Melatonin** should be given 20-30 minutes before desired sleep time. If child is unable to swallow tablets, Bio-Melatonin will dissolve in a small amount of water if broken and stirred. The dose may be increased to 4-6mg if there is insufficient benefit after 1-2 weeks. If no benefit is seen after 2 weeks on the higher dose then melatonin should be stopped.16

Be sure to use it along with a good pre-bed routine. The bedroom should be dark and comfortable. It is important that it is free from electronic media (such as TVs, electronic games and phones) which may distract the child and make it difficult to sleep (referred to sleep tool kit)

**Duration of Treatment**

The duration of treatment is variable. The aim is to establish healthy sleep habits with the lowest effective dose of melatonin. It is suggested that at least six months of an improved sleep pattern should elapse before withdrawal takes place. Withdrawal should occur over a period of 3-4 weeks and change in sleep pattern observed. For some children however withdrawal is not successful and treatment may be necessary long term.

Some clinical experience from the National Child and Adolescent Learning Disability Psychiatry Network suggests that the efficacy may be lost if melatonin is prescribed for longer than two years. It suggests that if the melatonin is withdrawn prior to this, sensitivity may be re-established and melatonin successfully re-introduced at a lower dose.
Reviewing Treatment
If treatment is successful, a trial reduction in the dose should be attempted after 6 months as some patients would have settled into a regular sleep pattern and may not need to continue at the same dose or may even be able to maintain sleep with no medication. If sleep patterns are maintained, dosage can be reduced by 2 mg every 4-6 weeks. If the difficulties recur the original dose should be reinstated, but a further trial reduction should be attempted 6 months later.¹⁸

Monitoring
Patients should be followed up every three to six months to ensure continuing benefit of melatonin. Standard monitoring of growth and sexual development is recommended i.e. to check height, weight and pubertal development progress as expected.¹⁸

Licensing
There is only one licensed formulation of melatonin in the UK- Circadin® 2mg modified release tablet for short term treatment of primary insomnia in adults over ≥55 years.⁷ Circadin should be used first line as an off label indication in children and adolescents with sleep onset insomnia and delayed sleep phase syndromes in children with neurodevelopmental disorders.⁹ Circadin initiation and supervision should be carried out by a Specialist but can be continued by General Practice if shared care arrangements exists. Unlicencensed or off – label use of a licensed product may be prescribed if deemed appropriate by the prescribing clinician.⁸ Off label use of a licensed product is preferred to the prescription of an unlicensed product.⁹

Melatonin formulation/Cost

Table 1: Cost Breakdown

<table>
<thead>
<tr>
<th>Melatonin formulation</th>
<th>Cost (mls/capsule/tablet)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid Special 3mg/5ml</td>
<td>Est. £8.20/5ml</td>
</tr>
<tr>
<td>Capsules Special 5mg</td>
<td>£1.69/ capsule</td>
</tr>
<tr>
<td>Capsules(special) 10mg</td>
<td>£2.02/capsule</td>
</tr>
<tr>
<td>Tablets (special)</td>
<td>£2.15/tablet</td>
</tr>
<tr>
<td>Bio-Melatonin (Pharmanord) Special</td>
<td>£1.21/tablet</td>
</tr>
<tr>
<td>Circadin</td>
<td>£0.51/tablet</td>
</tr>
<tr>
<td>Product</td>
<td>Average Price</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Circadin tables 2mg M/R*</td>
<td></td>
</tr>
<tr>
<td>Capsules 3mg M/R*</td>
<td></td>
</tr>
<tr>
<td>Bio-Melatonin tablets 3mg</td>
<td></td>
</tr>
<tr>
<td>Tablets 3mg</td>
<td></td>
</tr>
<tr>
<td>Capsules 3mg</td>
<td></td>
</tr>
<tr>
<td>Capsules 2mg</td>
<td></td>
</tr>
<tr>
<td>Bio-Tech capsules 3mg</td>
<td></td>
</tr>
<tr>
<td>Capsules 5mg</td>
<td></td>
</tr>
<tr>
<td>Capsules 1mg</td>
<td></td>
</tr>
<tr>
<td>Oral Solution 5mg/5ml, 200ml*</td>
<td></td>
</tr>
<tr>
<td>Oral Suspension 5mg/5ml, 200ml*</td>
<td></td>
</tr>
<tr>
<td>Liquid Special 3mg/5ml, 200ml</td>
<td></td>
</tr>
</tbody>
</table>

*Figure 1: Cost differences between melatonin formulations.
Specialist Paediatrician responsibilities
- Initiate melatonin and titrate as appropriate.
- Monitor response and adverse effects pre/post titration.
- Regular reviews of sleep pattern and melatonin use.
- Provide adequate carer/parent sleep and melatonin information.
  (www.medicinesforchildren.org.uk/search-for-a-leaflet/melatonin-for-sleep-disorders)
- Notification of reviews and changes to GP and all relevant professionals.

GP/ Primary Health Care Professional responsibilities
- *Melatonin shared care arrangements currently do not exist within Hertfordshire.
- Notification of patients with rebound difficulties following discontinuation of melatonin to Specialist Services.
- GP/Health professional to ascertain that good sleep hygiene is established before referral/notification to Specialist Services.

Hospital Pharmacist responsibilities
- Ensure that the Pharmacy holds sufficient stocks of Circadin and Bio-melatonin to meet patients needs
- If there are supply problems to keep patients/carers informed
- Counsel patients on their melatonin prescriptions
- Provide reports for the directorate on melatonin expenditure

Parent/Carer and patient responsibilities
- Continue to implement good sleep hygiene even when the child is on medication.
- Complete a 3 week sleep diary and questionnaire every 3-6 months ideally during a washout period on school holidays to ascertain the need to continue on melatonin.
- Ensure good compliance with medication and notify the Specialist if child is no longer taking or requiring melatonin.
References:


12. East/North Hertfordshire NHS Trust Pharmacy Department 2014

13 Flynn Pharmaceuticals Company drug costs information

14 London Procurement Partnership Bulletin (LPP)

15. SPC- Summary of Product Characteristics last updated on the eMC: 02/09/2013


17. Sleep Health Foundation


20. NICE clinical guideline 53: Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy)